$OM
Outset Medical, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023060476 Filed on November 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $30.51M $30.36M
YoY Change -4.69% 9.37%
Cost Of Revenue $22.80M $23.21M
YoY Change -14.73% -0.94%
Gross Profit $7.712M $7.157M
YoY Change 46.25% 65.06%
Gross Profit Margin 25.28% 23.57%
Selling, General & Admin $32.53M $36.54M
YoY Change -3.33% 13.2%
% of Gross Profit 421.85% 510.48%
Research & Development $12.53M $16.08M
YoY Change 9.51% 23.1%
% of Gross Profit 162.5% 224.62%
Depreciation & Amortization $1.450M $1.460M
YoY Change 14.26% 11.11%
% of Gross Profit 18.8% 20.4%
Operating Expenses $45.07M $52.61M
YoY Change -0.07% 16.05%
Operating Profit -$37.35M -$45.45M
YoY Change -6.2% 10.87%
Interest Expense -$1.135M $3.213M
YoY Change 500.53% 466.67%
% of Operating Profit
Other Income/Expense, Net $2.573M
YoY Change 219.63%
Pretax Income -$38.49M -$46.09M
YoY Change -6.99% 13.08%
Income Tax $112.0K $86.00K
% Of Pretax Income
Net Earnings -$38.60M -$46.18M
YoY Change -6.86% 13.24%
Net Earnings / Revenue -126.53% -152.1%
Basic Earnings Per Share -$0.93
Diluted Earnings Per Share -$0.77 -$0.93
COMMON SHARES
Basic Shares Outstanding 50.20M 49.79M
Diluted Shares Outstanding 49.91K

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $133.4M $128.9M
YoY Change -53.61% -43.33%
Cash & Equivalents $68.51M $36.30M
Short-Term Investments $64.88M $92.65M
Other Short-Term Assets $5.700M $6.000M
YoY Change -13.6% 27.28%
Inventory $49.22M $48.26M
Prepaid Expenses
Receivables $32.98M $35.49M
Other Receivables $0.00 $0.00
Total Short-Term Assets $291.2M $283.8M
YoY Change -22.06% -8.46%
LONG-TERM ASSETS
Property, Plant & Equipment $13.27M $13.77M
YoY Change -16.4% -11.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $605.0K $961.0K
YoY Change -48.11% 148.96%
Total Long-Term Assets $22.58M $23.78M
YoY Change -14.69% -57.33%
TOTAL ASSETS
Total Short-Term Assets $291.2M $283.8M
Total Long-Term Assets $22.58M $23.78M
Total Assets $313.8M $307.6M
YoY Change -21.57% -15.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.827M $2.880M
YoY Change 866.33% 99.45%
Accrued Expenses $32.01M $34.70M
YoY Change -10.03% 1.94%
Deferred Revenue $11.73M $10.83M
YoY Change 35.38% 38.38%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $55.32M $53.02M
YoY Change 6.49% 6.81%
LONG-TERM LIABILITIES
Long-Term Debt $130.1M $96.78M
YoY Change 35.06% 224.47%
Other Long-Term Liabilities $5.479M $5.700M
YoY Change -6.18% -20.25%
Total Long-Term Liabilities $130.1M $96.78M
YoY Change 35.06% 224.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $55.32M $53.02M
Total Long-Term Liabilities $130.1M $96.78M
Total Liabilities $190.9M $155.5M
YoY Change 23.87% 79.51%
SHAREHOLDERS EQUITY
Retained Earnings -$961.7M -$923.1M
YoY Change 21.89% 23.49%
Common Stock $1.085B $1.075B
YoY Change 4.74% 4.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $122.9M $152.1M
YoY Change
Total Liabilities & Shareholders Equity $313.8M $307.6M
YoY Change -21.57% -15.91%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$38.60M -$46.18M
YoY Change -6.86% 13.24%
Depreciation, Depletion And Amortization $1.450M $1.460M
YoY Change 14.26% 11.11%
Cash From Operating Activities -$24.44M -$34.00M
YoY Change -29.17% -0.91%
INVESTING ACTIVITIES
Capital Expenditures $1.050M $780.0K
YoY Change -50.21% -128.46%
Acquisitions
YoY Change
Other Investing Activities $24.48M $30.59M
YoY Change -149.31% 33.58%
Cash From Investing Activities $23.43M $29.80M
YoY Change -145.27% 47.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 33.23M 4.100M
YoY Change -49.34% 61.86%
NET CHANGE
Cash From Operating Activities -24.44M -34.00M
Cash From Investing Activities 23.43M 29.80M
Cash From Financing Activities 33.23M 4.100M
Net Change In Cash 32.22M -100.0K
YoY Change -255.97% -99.14%
FREE CASH FLOW
Cash From Operating Activities -$24.44M -$34.00M
Capital Expenditures $1.050M $780.0K
Free Cash Flow -$25.49M -$34.78M
YoY Change -30.38% 10.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001484612
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39513
dei Entity Registrant Name
EntityRegistrantName
Outset Medical, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0514392
dei Entity Address Address Line1
EntityAddressAddressLine1
3052 Orchard Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
San Jose
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95134
dei City Area Code
CityAreaCode
669
dei Local Phone Number
LocalPhoneNumber
231-8200
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
OM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
50204570
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36297000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
73222000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
157701000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
214280000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
35493000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
28070000
CY2023Q3 us-gaap Inventory Net
InventoryNet
48257000
CY2022Q4 us-gaap Inventory Net
InventoryNet
51476000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6026000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6597000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
283774000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
373645000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3329000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3311000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13774000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15876000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5713000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6117000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
961000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1166000
CY2023Q3 us-gaap Assets
Assets
307551000
CY2022Q4 us-gaap Assets
Assets
400115000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2880000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
603000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
21544000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
21519000
CY2023Q3 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12160000
CY2022Q4 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16227000
CY2023Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
4068000
CY2022Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
3620000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10828000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
8662000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1544000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1318000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
53024000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51949000
CY2023Q3 om Accrued Interest Noncurrent
AccruedInterestNoncurrent
680000
CY2022Q4 om Accrued Interest Noncurrent
AccruedInterestNoncurrent
113000
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
99000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
151000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4901000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5576000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
96784000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13059000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
96336000
CY2023Q3 us-gaap Liabilities
Liabilities
155488000
CY2022Q4 us-gaap Liabilities
Liabilities
154125000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50173000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50173000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48465000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48465000
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
50000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
48000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1075413000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1035456000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-253000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-564000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-923147000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-788950000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
152063000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
245990000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
307551000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
400115000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30362000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27761000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
99869000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83368000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23205000
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23425000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
78581000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
70808000
CY2023Q3 us-gaap Gross Profit
GrossProfit
7157000
CY2022Q3 us-gaap Gross Profit
GrossProfit
4336000
us-gaap Gross Profit
GrossProfit
21288000
us-gaap Gross Profit
GrossProfit
12560000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16076000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44775000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37411000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
24720000
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22276000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
74038000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
65851000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11815000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10000000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34892000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30493000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
52611000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
45335000
us-gaap Operating Expenses
OperatingExpenses
153705000
us-gaap Operating Expenses
OperatingExpenses
133755000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-45454000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-40999000
us-gaap Operating Income Loss
OperatingIncomeLoss
-132417000
us-gaap Operating Income Loss
OperatingIncomeLoss
-121195000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2573000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
805000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7889000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1384000
CY2023Q3 us-gaap Interest Expense
InterestExpense
3213000
CY2022Q3 us-gaap Interest Expense
InterestExpense
567000
us-gaap Interest Expense
InterestExpense
9258000
us-gaap Interest Expense
InterestExpense
1470000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46094000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40761000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-133786000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-121281000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
86000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
411000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
231000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-46180000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-40781000
us-gaap Net Income Loss
NetIncomeLoss
-134197000
us-gaap Net Income Loss
NetIncomeLoss
-121512000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.54
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49913
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3900000
om Non Cash Lease Expense
NonCashLeaseExpense
919000
om Non Cash Lease Expense
NonCashLeaseExpense
826000
om Non Cash Interest Expense
NonCashInterestExpense
1377000
om Non Cash Interest Expense
NonCashInterestExpense
426000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49913
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48129
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48129
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49364
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49364
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47835
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47835
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-46180000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-40781000
us-gaap Net Income Loss
NetIncomeLoss
-134197000
us-gaap Net Income Loss
NetIncomeLoss
-121512000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
140000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
21000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
311000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-750000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46040000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40760000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-133886000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-122262000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
245990000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4594000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
684000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8538000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
451000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43971000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216286000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1043000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10105000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-280000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44046000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
183108000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2916000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1186000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10893000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
140000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-46180000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
152063000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
374081000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2063000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1660000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5006000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-465000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36892000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
345453000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1042000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7414000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-306000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-43839000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
309764000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2139000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
530000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7430000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
21000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-40781000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
279103000
us-gaap Net Income Loss
NetIncomeLoss
-134197000
us-gaap Net Income Loss
NetIncomeLoss
-121512000
us-gaap Share Based Compensation
ShareBasedCompensation
29536000
us-gaap Share Based Compensation
ShareBasedCompensation
19850000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4364000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5099000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1081000
om Provision For Inventories
ProvisionForInventories
672000
om Provision For Inventories
ProvisionForInventories
1617000
om Other Non Cash Items
OtherNonCashItems
247000
om Other Non Cash Items
OtherNonCashItems
26000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7564000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3079000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2607000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
17692000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-440000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-728000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2251000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-575000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
25000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-5675000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4108000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2476000
om Increase Decrease In Accrued Warranty Liability
IncreaseDecreaseInAccruedWarrantyLiability
447000
om Increase Decrease In Accrued Warranty Liability
IncreaseDecreaseInAccruedWarrantyLiability
-248000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2114000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1315000
om Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-962000
om Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-844000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-106931000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-111222000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2387000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6216000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
121262000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
168615000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
183250000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
160284000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
59601000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-14547000
om Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases
10423000
om Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases
7433000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
135000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10423000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7298000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36907000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-118471000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76533000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
215659000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39626000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
97188000
us-gaap Income Taxes Paid
IncomeTaxesPaid
403000
us-gaap Income Taxes Paid
IncomeTaxesPaid
334000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3664000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
96784000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
96336000
om Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod
0.50
us-gaap Interest Paid Net
InterestPaidNet
1836000
us-gaap Interest Paid Net
InterestPaidNet
1044000
om Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
962000
om Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
844000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
207000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
556000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
514000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Net Income Loss
NetIncomeLoss
-134200000
us-gaap Net Income Loss
NetIncomeLoss
-121500000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-923100000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
194000000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3300000
CY2023Q3 om Cash Cash Equivalents Restricted Cash And Short Term Investments
CashCashEquivalentsRestrictedCashAndShortTermInvestments
197300000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30362000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27761000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
99869000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
83368000
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
10900000
CY2023Q3 om Revenue Performance Obligation1
RevenuePerformanceObligation1
10800000
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2023Q3 om Revenue Performance Obligation1
RevenuePerformanceObligation1
100000
CY2023Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1700000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
7900000
om Debt Securities Available For Sale Remaining Contractual Maturities Period
DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod
one month to thirteen months
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
92648000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
255000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
154534000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
615000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
3300000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
3300000
om Cash Cash Equivalents And Restricted Cash
CashCashEquivalentsAndRestrictedCash
<p style="text-indent:5.067%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:67.08%;"></td> <td style="width:1.622%;"></td> <td style="width:1%;"></td> <td style="width:12.837%;"></td> <td style="width:1%;"></td> <td style="width:1.622%;"></td> <td style="width:1%;"></td> <td style="width:12.837%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="6" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30,</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">36,297</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">63,877</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3,329</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">33,311</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;text-indent:10pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">39,626</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">97,188</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36297000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63877000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
3329000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
33311000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39626000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97188000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
21989000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
20623000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
8968000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
9086000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
17300000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
21767000
CY2023Q3 us-gaap Inventory Net
InventoryNet
48257000
CY2022Q4 us-gaap Inventory Net
InventoryNet
51476000
CY2023Q3 om Accrued Inventory Current
AccruedInventoryCurrent
3345000
CY2022Q4 om Accrued Inventory Current
AccruedInventoryCurrent
5585000
CY2023Q3 om Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
914000
CY2022Q4 om Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
908000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1079000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1261000
CY2023Q3 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
2166000
CY2022Q4 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
1364000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4656000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7109000
CY2023Q3 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
12160000
CY2022Q4 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
16227000
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
100000000
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
100000000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3216000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10893000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7430000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29536000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
19850000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4938000
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4375000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4938000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4375000
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-060476-index-headers.html Edgar Link pending
0000950170-23-060476-index.html Edgar Link pending
0000950170-23-060476.txt Edgar Link pending
0000950170-23-060476-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
om-20230930.htm Edgar Link pending
om-20230930.xsd Edgar Link pending
om-ex31_1.htm Edgar Link pending
om-ex31_2.htm Edgar Link pending
om-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
om-20230930_cal.xml Edgar Link unprocessable
om-20230930_def.xml Edgar Link unprocessable
om-20230930_lab.xml Edgar Link unprocessable
om-20230930_pre.xml Edgar Link unprocessable
om-20230930_htm.xml Edgar Link completed
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending